Law360 (June 30, 2010, 2:22 PM EDT) -- Sanofi-Aventis SA said Wednesday that it would pay up to $560 million to buy biotechnology company TargeGen Inc. and commercialize one of its treatments for blood disorders.
The French pharmaceutical giant said it would make a $75 million up-front payment for rights to TargeGen's most advanced drug candidate, followed by milestone payments if the company meets certain goals, for a total of up to $560 million for the acquisition.
The deal is a further step to increase Sanofi's presence in the field of hematological malignancies, according to Marc Cluzel, Sanofi's executive vice president of research and development.
The privately held, San...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!